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OBJECTIVE—Insulin resistance is an independent risk factor
for the development of cardiovascular atherosclerosis. A key
step in the development of atherosclerosis is endothelial dys-
function, manifest by a reduction in bioactivity of nitric oxide
(NO). Insulin resistance is associated with endothelial dysfunc-
tion; however, the mechanistic relationship between these ab-
normalities and the role of impaired endothelial insulin signaling
versus global insulin resistance remains unclear.
RESEARCH DESIGN AND METHODS—To examine the
effects of insulin resistance speciﬁc to the endothelium, we
generated a transgenic mouse with endothelium-targeted over-
expression of a dominant-negative mutant human insulin recep-
tor (ESMIRO). This receptor has a mutation (Ala-Thr
1134)i ni t s
tyrosine kinase domain that disrupts insulin signaling. Humans
with the Thr
1134 mutation are insulin resistant. We performed
metabolic and vascular characterization of this model.
RESULTS—ESMIRO mice had preserved glucose homeostasis
and were normotensive. They had signiﬁcant endothelial dys-
function as evidenced by blunted aortic vasorelaxant responses
to acetylcholine (ACh) and calcium ionophore. Furthermore, the
vascular action of insulin was lost in ESMIRO mice, and insulin-
induced endothelial NO synthase (eNOS) phosphorylation was
blunted. Despite this phenotype, ESMIRO mice demonstrate
similar levels of eNOS mRNA and protein expression to wild
type. ACh-induced relaxation was normalized by the superoxide
dismutase mimetic, Mn(III)tetrakis(1-methyl-4-pyridyl) porphy-
rin pentachloride. Endothelial cells of ESMIRO mice showed
increased superoxide generation and increased mRNA expres-
sion of the NADPH oxidase isoforms Nox2 and Nox4.
CONCLUSIONS—Selective endothelial insulin resistance is suf-
ﬁcient to induce a reduction in NO bioavailability and endothelial
dysfunction that is secondary to increased generation of reactive
oxygen species. This arises independent of a signiﬁcant meta-
bolic phenotype. Diabetes 57:3307–3314, 2008
R
ecent changes in human lifestyle have led to a
striking increase in the incidence of obesity and
type 2 diabetes (1). Resistance to the effects of
insulin on its traditional target tissues (muscle,
liver, and adipose tissue) is a central pathogenic feature of
these disorders (2). Insulin resistance at a whole-body
level is an independent risk factor for the development of
atherosclerosis (3–8). A key pathogenic step in atherogen-
esis is the development of endothelial cell dysfunction,
manifest by a reduction in bioavailability of the antiath-
erosclerotic signaling molecule nitric oxide (NO) (9).
Consonant with this, longitudinal studies have shown that
impaired NO-dependent vasodilatation is a predictor of
future cardiac events and the development of coronary
artery atherosclerosis (10). Insulin resistance is associated
with endothelial dysfunction (11), and this may account at
least in part for its ultimately deleterious consequences. A
number of studies have suggested a reciprocal relationship
between insulin sensitivity and endothelial cell function
(12).
The mechanistic relationship between insulin resistance
and endothelial dysfunction remains unclear. Studies of
vascular function in models of insulin resistance are
complicated by the complex phenotype of type 2 diabetes,
which includes numerous factors that may inﬂuence en-
dothelial function, e.g., hyperinsulinemia, hyperglycemia,
hypertension, and hyperlipidemia. Therefore, if the rela-
tionship between insulin resistance and endothelial dys-
function in vivo is causative, the basis for this is difﬁcult to
establish. Nevertheless, there is evidence to suggest that
the direct effects of insulin on the endothelium or dis-
rupted endothelial insulin signaling may impact on endo-
thelial function. Insulin stimulates endothelial cell
production of NO (13), and, therefore, insulin resistance at
the level of the endothelium might be expected to be
associated with reduced insulin-stimulated NO. Recently,
Kahn and colleagues (14) generated a mouse with endo-
thelium-targeted deﬁciency of the insulin receptor to study
the impact of insulin resistance speciﬁc to the endothe-
lium on metabolic homeostasis. Endothelial cell function
and NO bioavailability were not addressed in this study.
In the current study, we report the effects of selective
disruption of insulin signaling in the endothelium in vivo,
achieved by endothelium-targeted overexpression of a
mutant human insulin receptor under control of the tie-2
promoter (endothelium-speciﬁc mutant insulin receptor
overexpressing [ESMIRO] mice). This mutant receptor has
an alanine residue replaced by Thr
1134, resulting in mark-
edly impaired insulin signaling and severe insulin resis-
tance in heterozygous human subjects (15). Thr
1134
receptors display normal ligand binding but are devoid of
detectable insulin-stimulated tyrosine kinase activity and
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DIABETES, VOL. 57, DECEMBER 2008 3307fail to mediate several of insulin’s biological effects, in-
cluding activation of the insulin signaling pathway (15,16).
Transgenic mice overexpressing this mutant receptor in
skeletal muscle have blunting of insulin-mediated insulin
receptor substrate (IRS)-1 and phosphatidylinositol 3-ki-
nase (PI 3-kinase) phosphorylation (17). Although genetic
defects involving the insulin receptor are rare, impaired
insulin-mediated receptor kinase activity and impaired
activation of the insulin signaling pathway are character-
istic of obese and insulin-resistant type 2 diabetic humans
(18). Here, we report the effects of overexpression of this
receptor in the endothelium in vivo on metabolic and
blood pressure homeostasis and on endothelial function in
conduit vessels.
RESEARCH DESIGN AND METHODS
Endothelial cell–speciﬁc transgene overexpression was achieved using the
murine Tie2 promoter and intronic enhancer as previously described (19). A
Thr
1134 mutation was introduced into cDNA encoding the human insulin
receptor by site-directed mutagenesis (15). The plasmid pHHNS was a gift
from Keith Channon (University of Oxford, Oxford, U.K.). After excision of the
LacZ sequence with SbfI and MluI (19), the Thr
1134 mutant human insulin
receptor cDNA was cloned into pHHNS (Fig. 1A). Plasmid ﬁdelity and
orientation were conﬁrmed using standard DNA sequencing and PCR analysis.
The transgene Tie2-hIR was excised with SalI, puriﬁed, and microinjected
into fertilized eggs from superovulated C57BL/6  CBA mice. Potential
founders were screened by genotyping of genomic DNA from tail lysates using
primers speciﬁc for the human insulin receptor (forward, 5-GGT GGC AGC
TTT CCC CAA CAC T; reverse, 5-AGC CTT GGC TTC AGG CAT GGT C-3).
Animals were backcrossed eight times onto a C57BL/6J background. All
studies were comparisons of male ESMIRO mice aged 8–10 weeks and age-
and sex-matched wild-type littermates. Morphological assessment was per-
formed in 8- to 10-week-old male mice (20). Two lines of ESMIRO mice were
generated, and experiments were performed in both lines to exclude a
positional effect of transgene integration into the murine genome.
Semiquantitative and real-time RT-PCR. Total RNA was extracted from a
variety of tissues using an RNeasy Mini kit (Qiagen). Equal quantities of RNA
were reverse transcribed using Superscript II RT (Invitrogen) and random
decamer oligonucleotides. To assess transgene expression, PCR was per-
formed using primers speciﬁc for the human insulin receptor (forward,
5-GGT GGC AGC TTT CCC CAA CAC T; reverse, 5-AGC CTT GGC TTC AGG
CAT GGT C-3).
Real-time PCR analysis of endothelial NO synthase (eNOS), NOX2, NOX4,
and -actin expression was performed (eNOS forward, GGGAAAGCTGCAG-
GTATTTGAT, and reverse, CACTGTGATGGCTGAACGAAGA; Nox2 forward,
ACTCCTTGGGTCAGCACTGG, and reverse, GTTCCTGTCCAGTTGTCTTCG;
Nox4 forward, TGAACTACAGTGAAGATTTCCTTGAAC, and reverse, GA-
CACCCGTCAGACCAGGAAT; and -actin forward, CGTGAAAAGATGACCCA-
GATCA, and reverse, TGGTACGACCAGAGGCATACAG) (20). The standard
curve method was used, and results are normalized to -actin expression.
Immunohistochemistry. Thoracic aorta was excised and mounted vertically
in OCT embedding matrix (CellPath, Powys, U.K.) before freezing in cold
isopentane. Eight-micrometer transverse sections were ﬁxed in paraformal-
dehyde (4% in PBS, 30 min). A human-speciﬁc anti-insulin receptor antibody (1
in 200, 30 min; E5844; Spring Bioscience, Fremont, CA) was used, which does
not cross-react with the murine insulin receptor. A Vector M.O.M. immuno-
detection kit (Vector Laboratories, Burlingame, CA) reduced background
staining of endogenous mouse immunoglobulins. Antibody staining was
visualized using a secondary antibody conjugated to ﬂuorophores (Alexa
Fluor Dyes; Molecular Probes). Aortic sections were also probed with
anti–von Willebrand factor antibody (Sigma-Aldrich, Gillingham, U.K.).
eNOS and phospho-eNOS (Ser
1177) protein expression. Fasted mice
were anesthetized. An injection of either human recombinant insulin (5 units;
Actrapid; NovoNordisk, Bagsvaerd, Denmark) or saline vehicle (0.9% NaCl)
was administered via the inferior vena cava. After 5 min, the thoracic aorta
was excised. Immunoblotting was performed on total aortic tissue homoge-
nates using mouse monoclonal antibodies against total murine eNOS and
phospho-eNOS (Ser
1177) or a rabbit polyclonal antibody against -actin (20).
Metabolic assessment. Intraperitoneal glucose and insulin tolerance tests
were performed in conscious fasted mice. Plasma insulin was measured by
enzyme-linked immunoassay using mouse insulin standards. Fasting triglyc-
erides and fasting free fatty acids were measured by colorimetry (20,21).
Homeostasis model assessment of insulin resistance (HOMA-IR) was calcu-
lated from fasting insulin and glucose measurements.
Blood pressure. Systolic blood pressure was measured using tail cuff
plethysmography (20,21).
Aortic vascular function. Vascular function was studied in aortic rings
mounted in an organ bath as described previously (20,21). Cumulative dose
responses to phenylepherine (1 nmol/l to 10 mol/l) were measured. Phe-
nylepherine constriction responses were reassessed after incubation with
insulin (100 mU/ml; 2 h; Actrapid) (20). Relaxation responses to acetylcholine
(ACh; 1 nmol/l to 10 mol/l), A23187 (1 nmol/l to 1 mol/l), and sodium
nitroprusside (SNP; 0.1 nmol/l to 1 mol/l) were then measured. ACh
relaxation experiments were repeated after incubation with the SOD mimetic
Mn(III)tetrakis(1-methyl-4-pyridyl) porphyrin pentachloride (MnTMPyP; 10
mol/l; 30 min) (22).
Coronary microvascular endothelial cell isolation. Six mouse hearts
were used for each preparation of coronary microvascular endothelial cells
(CMECs) as described previously (23,24).
Vascular superoxide production. Three different methods were used to
detect superoxide. First, in situ reactive oxygen species (ROS) generation by
CMECs was assessed using dihydroethidium (DHE) ﬂuorescence (2 mol/l; 5
min) as previously reported (24,25). CMECs were grown to 70% conﬂuence
before exposure to DHE. Peak ﬂuorescence intensity per cell was quantiﬁed
microscopically using a computerized image analysis system (Improvision)
from at least 30 cells per group; n  6 mice per CMEC isolation.
Second, 5 mol/l lucigenin-enhanced chemiluminescence was performed
on homogenates of CMECs or aorta to assess NADPH-dependent superoxide
production (22,23). In some experiments, one of the following agents was
preincubated for 10 min: 20 mmol/l tiron, 10 mol/l diphenyleneiodonium
(DPI), or 100 mol/l NG-nitro-L-arginine methyl ester (L-NAME).
Finally, functional evidence for the generation of superoxide was obtained
by assessing the effect of an SOD mimetic (MnTMPyP) on aortic relaxation
responses to ACh in the ESMIRO model (24).
A
B
C
Tie2 promoter
2.1kb 4.1kb 10kb
hIR Transgene   Tie2 intronic enhancer
SV40pA F R
-ve      Con    WT     ES1    ES2
GAPDH control
Transgene 172 bp
-RT
-ve con Lu Li Sp Ki He Lu Li Sp Ki He
172 bp
D
ESMIRO  WT 
Endothelium  Endothelium 
FIG. 1. A: Schematic of the Tie2/mutant human insulin receptor
transgene. Forward (F) and reverse (R) oligonucleotide primers spe-
ciﬁc for the human insulin receptor are represented. B: PCR of genomic
DNA from tail lysates using the primers demonstrates incorporation of
the transgene into genomic DNA in both lines of ESMIRO mice. C:
Transgene expression in different organs from ESMIRO mice. ESMIRO
mice demonstrated increased transgene expression in lung (Lu) and
kidney (Ki) compared with liver (Li), spleen (SP), and heart (He). ve,
negative control; con, positive control (construct); RT-ve, reverse
transcriptase negative. D: Immunohistochemistry of sections of tho-
racic aorta from ESMIRO and wild-type (WT) mice. Staining with an
antibody speciﬁc for the human insulin receptor demonstrated trans-
gene protein expression in ESMIRO but not wild-type endothelium
(magniﬁcation 400). The transgene colocalized in the endothelium
with von Willebrand factor (data not shown). BP, base pair. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase. (Please see http://dx.doi.
org/10.2337/db07-1111 for a high-quality digital representation of this
ﬁgure.)
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tration-response relationships were compared using two-way repeated-mea-
sures ANOVA. Half-maximal effective concentration (EC50) and maximal
response (Emax) were compared using a Student’s t test. One-way ANOVA
was used to analyze chemiluminescence data (Newman-Keuls multiple com-
parison test for post hoc analysis). Other variables were compared using
Student’s t test. P  0.05 taken as statistically signiﬁcant.
RESULTS
Endothelium-speciﬁc expression of Thr
1134 insulin
receptor. Endothelial cell–speciﬁc expression of mutant
Thr1134 receptors was achieved using a Tie-2 promoter/
intronic enhancer construct (26). Two lines of transgenic
mice were generated. Semiquantitative RT-PCR performed
on mRNA isolated from a range of organs from ESMIRO
mice demonstrated that transgene expression was greater
in endothelial-rich tissues such as lung and to a lesser
extent kidney as opposed to liver, spleen, and heart (Fig.
1C). Expression of mutant human insulin receptor protein
was conﬁrmed by immunohistochemistry on sections of
thoracic aorta using an antibody speciﬁc for the human
insulin receptor (Fig. 1D). Positive staining was found at
the luminal endothelial surface of ESMIRO mouse aorta
but not wild type. The transgene protein colocalized with
endothelial cells as labeled with the endothelial marker,
von Willebrand factor (data not shown).
Morphometric analysis. ESMIRO mice and their wild-
type littermates appeared morphologically similar. No
differences in fertility, lifespan, or behavior were ob-
served. Whole-body weight, mean organ weights, and
markers of adiposity were similar in ESMIRO and wild-
type mice (data not shown).
Metabolic homeostasis. It has been suggested that en-
dothelial cell insulin resistance might promote global
metabolic insulin resistance secondary to decreased insu-
lin-stimulated blood ﬂow to insulin-sensitive tissues (27–
29). However, metabolic characterization of the ESMIRO
mice did not support such a mechanism. ESMIRO and
wild-type mice demonstrated similar fasting blood glucose
levels (6.5  0.2 and 6.7  0.4 mmol/l, n  8) and fasting
serum insulin levels (0.34  0.03 and 0.30  0.03 ng/ml,
n  8) (Table 1). Glucose tolerance testing demonstrated
no difference between the two groups (n  11, P  0.05;
data not shown). Insulin tolerance testing suggested a
trend toward improved insulin sensitivity in ESMIRO mice
(n  11, P  0.05 by repeated-measures ANOVA; data not
shown). Serum insulin levels rose equally in response to
an intraperitoneal glucose challenge (ESMIRO, 0.78  0.10
and wild type, 0.72  0.06 ng/ml). HOMA-IRs were similar
in ESMIRO and wild-type mice (2.1  0.2 and 2.4  0.6,
respectively; Table 1). Fasting serum triglycerides (0.80 
0.08 and 0.98  0.14 mmol/l, respectively) and free fatty
acids (0.92  0.1 and 1.0  0.2 mmol/l, respectively) were
similar in both groups.
Blood pressure regulation. It has been previously sug-
gested that insulin resistance at the vascular level may
lead to hypertension (30). However, ESMIRO and wild-
type mice had similar systolic blood pressures (Table 1;
131  4 and 129  4 mmHg, n  8).
Effect of endothelial cell–speciﬁc mutant receptor
expression on vasoconstrictor responses and the ac-
tions of insulin in conduit vessels. Isolated aortic rings
of ESMIRO mice and wild-type mice had similar constric-
tor responses to 40 mmol/l KCl (Emax 0.68  0.04 and
0.73  0.06 g, ESMIRO and wild type, respectively) and
phenylepherine (Fig. 2A; ESMIRO, Emax 0.84  0.06 g,
EC50 227  43 nmol/l; and wild-type, Emax 0.87  0.05 g,
EC50 242  26 nmol/l).
Acute exposure to insulin blunts the vasoconstrictor
response to phenylepherine through an endothelial- and
NO-dependent mechanism (20). Consistent with this, ex-
posure of wild-type aorta to insulin caused a signiﬁcant
blunting of maximal phenylepherine-induced constriction
(compare Fig. 2A and B). However, this effect was lost in
ESMIRO mice (Fig. 2B; phenylepherine plus insulin Emax
0.83  0.07 and 0.59  0.06 g, ESMIRO and wild type,
respectively; P  0.05).
The endothelial-dependent vasodilator effect of insulin
involves Akt-mediated phosphorylation of eNOS on resi-
due Ser
1177, resulting in enhanced NO production (31). To
investigate the effect of transgene expression on this effect
of insulin on endothelial cells, we studied eNOS protein
expression and Ser
1177 eNOS phosphorylation in the tho-
racic aorta of ESMIRO and wild-type mice exposed to
insulin in vivo. Basal levels of eNOS protein expression
were similar in ESMIRO and wild-type mice (Fig. 2C and
D). After administration of insulin, wild-type mice demon-
strated a signiﬁcant increase in the phospho-eNOS–to–
eNOS ratio (1.00 vs. 1.78  0.15, P  0.05); this effect was
absent in ESMIRO mice (0.63  0.1 vs. 0.61  0.1, NS).
Therefore, overexpression of the mutant Thr1134 insulin
receptor leads to impaired endothelial insulin signaling. A
similar result was demonstrated in complementary exper-
iments performed using lung tissue (data not shown).
Effect of transgene expression on endothelial-depen-
dent vasodilator responses in conduit vessels.
Vasorelaxation to the agonist ACh was blunted in ESMIRO
mice compared with wild type (Fig. 3A;E m a x6 8 6 and
102  6%, ESMIRO and wild type, respectively, P  0.01;
EC50 180  73 and 114  37 nmol/l, ESMIRO and wild type,
respectively, NS). Similarly, vasodilator responses to the
calcium ionophore A23187 were also blunted (Fig. 3B;
Emax 51  12 and 79  8%, ESMIRO and wild type,
respectively, P  0.05; EC50 119  29 and 39  8 nmol/l,
ESMIRO and wild type, respectively, P  0.01). However,
responses to SNP were similar in ESMIRO and wild-type
mice (Fig. 3C;E m a x1 0 9 1 and 110  2%, ESMIRO and
wild type, respectively, NS; EC50 23  6 and 17  2 nmol/l,
ESMIRO and wild type, respectively, NS). These data
TABLE 1
Metabolic characteristics and systolic blood pressure of ESMIRO
mice compared with their wild-type littermates
Wild type ESMIRO P value
Fasting blood sugar
(mmol/l) 6.7  0.4 6.5  0.2 0.68
Postglucose blood sugar
(mmol/l) 16.2  1.0 14.4  0.7 0.17
Random blood glucose
(mmol/l) 11.1  1.1 13.3  1.1 0.19
Fasting insulin (ng/ml) 0.30  0.03 0.34  0.03 0.27
Postglucose insulin
(ng/ml) 0.72  0.06 0.78  0.10 0.61
HOMA-IR 2.4  0.6 2.1  0.2 0.63
Fasted triglycerides
(mmol/l) 0.98  0.14 0.8  0.08 0.28
Fasted free fatty acids
(mmol/l) 1.0  0.2 0.92  0.1 0.49
Systolic blood pressure
(mmHg) 131  4 129  4 0.68
Data are means  SE (n  8). No signiﬁcant differences were noted
between the two groups.
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thelial dysfunction.
A similar vascular phenotype was seen in a second line
of ESMIRO mice (data not shown). These results exclude
a positional effect after transgene integration into the
murine genome.
Aortic superoxide production and its impact on en-
dothelial function. A common mechanism of impaired
endothelium-dependent vasodilatation is an increased pro-
duction of ROS (32–35). We therefore assessed the effects
of a SOD mimetic on ACh-induced relaxation in aortae.
MnTMPyP restored vasorelaxation responses to ACh in
ESMIRO aortae (Fig. 4A;E m a x8 3 5 and 86  7%,
ESMIRO and wild type, respectively, NS), consistent with
a role for increased aortic superoxide production in me-
diating the endothelial dysfunction seen in ESMIRO mice.
We assessed NADPH-dependent superoxide production
by homogenates of thoracic aortae using lucigenin-en-
hanced chemiluminescence. Consistent with the func-
tional ﬁndings in aortic vasodilatation experiments,
ESMIRO aortae demonstrated increased superoxide pro-
duction compared with wild type (Fig. 4B; 12.6.0 
0.5(106) vs. 8.1  0.4(106) integrated light units, P 
0.001). ESMIRO and wild-type superoxide production
were almost completely abolished by the antioxidant tiron
(P  0.001) or the ﬂavoprotein inhibitor DPI (P  0.001).
The NO synthase inhibitor L-NAME had no effect on
NADPH-dependent superoxide production in either group.
CMEC superoxide production. DHE ﬂuorescence of
cultured CMECs conﬁrmed that ESMIRO mice have in-
creased superoxide at the level of the endothelial cell
compared with wild type (2,819  151 and 1,439  129,
P  0.001, n  6 mice per group, Fig. 5A). This was
conﬁrmed by lucigenin-enhanced chemiluminescence per-
formed on CMEC homogenates (Fig. 5B). As in experi-
ments in whole aorta, NADPH-dependent superoxide
production in CMECs was inhibited by tiron and DPI but
not by L-NAME.
Expression of eNOS, Nox2, and Nox4 mRNA in
CMECs and aorta. Consistent with the equal eNOS
protein expression previously demonstrated in aorta (Fig.
2), there was no difference between groups in eNOS mRNA
expression in CMECs (data not shown). However, a signiﬁ-
cant (approximately twofold) increase in mRNA expression
of the NADPH oxidase isoforms Nox2 and Nox4 was seen in
ESMIRO aortae (Fig. 6). Upregulation was even more pro-
nounced in CMECs, especially that of Nox2.
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FIG. 2. The action of insulin on the aorta of ESMIRO and wild-type (WT) mice. A: Wild-type (f) and ESMIRO (‚) mice had similar aortic
vasoconstrictor responses to phenylepherine. B: Incubation with insulin (100 mU/ml) for 2 h signiﬁcantly blunted this response in wild-type mice
but had no effect in ESMIRO mice (n  8). C and D: Immunoblot of eNOS and phospho-eNOS protein expression in wild-type and ESMIRO aortae
(n  5). There was no difference in eNOS protein expression between the two groups (corrected for -actin). However, wild-type phospho-eNOS
expression was signiﬁcantly greater than that of ESMIRO mice at baseline. Furthermore, a signiﬁcant increment in eNOS phosphorylation at
Ser
1177 was seen in wild-type mice after insulin injection. No such increment was seen in ESMIRO mice. *P < 0.05 wild type vs. ESMIRO; #P <
0.05 wild type vs. wild type  insulin.
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The present study demonstrates a number of important
ﬁndings that add to our understanding of the role of insulin
resistance in endothelial cell homeostasis: 1) The induc-
tion of endothelial cell–speciﬁc insulin resistance leads to
markedly reduced NO bioavailability in conduit vessels
without signiﬁcant alteration in global insulin sensitivity.
2) Possible mechanisms include reduced NO bioavailabil-
ity secondary to increases in aortic and endothelial cell
superoxide production. 3) Endothelial cell–speciﬁc insu-
lin resistance does not alter systolic blood pressure. 4)
Insulin action at the level of the endothelium is not a
prerequisite for maintenance of normal blood glucose
homeostasis.
Modulating insulin signaling with a mutant insulin
receptor. To address the role of impaired insulin signaling
speciﬁcally in the endothelium (as opposed to global
impairment in all tissues), we generated a novel murine
model of endothelial cell–speciﬁc insulin resistance by
overexpressing a mutant human insulin receptor in the
endothelium (15).
Insulin binding to a normal insulin receptor leads to
activation of the tyrosine kinase and a rapid cascade of
phosphorylation, leading to activation of multiple intracel-
lular substrates (36). The function of these substrates is to
reversibly bridge the activated insulin receptor to a variety
of distal signaling molecules. As discussed above, emerg-
ing evidence supports eNOS as one of these distal signal-
ing molecules in endothelial cells (37).
Recently, insulin receptors with a mutation where
Ala
1134 is replaced by Thr in the tyrosine kinase domain of
the -subunit have been found in humans (15). In an
affected family, heterozygotes were severely insulin resis-
tant. In in vitro transfection studies, insulin receptor
processing, expression on the cell surface, and afﬁnity of
insulin binding to the mutant receptor were normal. The
ability of insulin to stimulate receptor autophosphoryla-
tion and tyrosine kinase activity was, however, substan-
tially impaired. Moreover, cells expressing Thr
1134 insulin
receptors had blunted insulin-stimulated glucose uptake
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ionophore A23187 (B) compared with wild-type (WT) littermates (f).
C: Relaxation responses to SNP were similar in ESMIRO and wild-type
mice. n  8, *P < 0.05.
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FIG. 4. Assessment of aortic superoxide production in ESMIRO and
wild-type (WT) mice. ESMIRO mice demonstrate impaired relaxation
responses to ACh at baseline. (see Fig. 3). A: Importantly, ESMIRO
ACh responses (‚) were normalized after incubation with the SOD
mimetic, 10 mol/l MnTMPyP, providing physiological evidence that
increased superoxide production in ESMIRO aortae contributes to the
impaired relaxation responses seen. B: Lucigenin-enhanced chemilumi-
nescence was performed on aortic homogenates. ESMIRO aortae dem-
onstrated increased superoxide production compared with wild type.
In both groups, superoxide production was completely inhibited by the
ROS scavenger tiron or the ﬂavoprotein inhibitor DPI. There was no
signiﬁcant inhibition with the NOS inhibitor L-NAME. These data
suggest a role for NADPH oxidase as the major source of the increased
superoxide in the ESMIRO aorta. *P < 0.001 with inhibitor compared
with wild-type baseline; #P < 0.001 with inhibitor compared with
ESMIRO baseline. ILU, integrated light units.
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tissue-speciﬁc transgenic mice overexpressing Thr
1134 in-
sulin receptors in skeletal muscle. These mice were a
model of nondiabetic insulin resistance and had reduced
responses to insulin during insulin tolerance testing and
elevated serum glucose and insulin levels when fed ad
libitum.
Characterization of an endothelial cell–speciﬁc model
of insulin resistance (ESMIRO mice). ESMIRO mice
expressed mutant human insulin receptors in the endothe-
lium, as conﬁrmed by immunohistochemistry. Functional
impairment of endothelial insulin signaling was conﬁrmed
in two ways. First, the endothelium-dependent, NO-medi-
ated vasorelaxant action of insulin (to reduce the vasocon-
strictor response to phenylepherine) (20) was signiﬁcantly
impaired in aortic rings from ESMIRO mice compared
with wild type. Second, and consistent with this ﬁnding,
insulin-stimulated phosphorylation of eNOS at Ser
1177 was
also blunted in the aortae of ESMIRO mice. However, the
ESMIRO had similar metabolic responses to intraperito-
neal boluses of insulin and glucose when compared with
wild-type littermates, indicating that there was no decline
in global insulin sensitivity. Moreover, we detected no
differences in body weight, adiposity, plasma lipids, fasting
insulin, or HOMA. Despite no difference in metabolic
homeostasis, ESMIRO mice had a striking defect in endo-
thelium-dependent relaxation in aorta, attributable to an
unfavorable imbalance between the production of NO and
ROS. Therefore, there was a signiﬁcant divergence be-
tween the impact of impaired endothelial insulin signaling
on vascular function versus glucose homeostasis.
Endothelial insulin resistance and NO bioavail-
ability. Insulin resistance and type 2 diabetes are now
established as important risk factors for the development
of cardiovascular atherosclerosis (3,8,38). The alarming
increase in type 2 diabetes in children and young adults
and the fact that a substantial proportion of patients with
type 2 diabetes have coronary artery disease at presenta-
tion makes understanding the mechanisms underlying
accelerated atherosclerosis in insulin resistance of partic-
ular importance. Compelling evidence supports endothe-
lial cell dysfunction as a key early event in the
pathogenesis of atherosclerosis (9).
The bioavailability of NO is dependent on the balance
between its production by eNOS and its inactivation by
ROS. Classical activation of eNOS (e.g., by ACh) involves
a rise in intracellular Ca
2	 and binding of Ca
2	/calmodulin
to the enzyme. Recently, a Ca
2	-independent regulatory
pathway for eNOS stimulated by shear stress or insulin has
also been described (31). Both shear stress and insulin
increase endothelial NO production via the activation of PI
3-kinase and protein kinase B (PKB/Akt), which phosphor-
ylates eNOS on Ser
1177 (37). In addition, insulin upregu-
lates eNOS transcription in endothelial cells (39). In the
present study, impaired endothelial insulin signaling was
accompanied by reduced insulin-mediated vasodilation as
might be expected. Interestingly, ACh- and calcium iono-
phore–stimulated vasodilation were also signiﬁcantly im-
paired despite eNOS expression being unaffected. The
mechanism underlying this observed endothelial dysfunc-
tion appears to be an increase in endothelial cell and aortic
superoxide production. In a recent report, we demon-
strated that mice with global haploinsufﬁciency of the
insulin receptor (IRKO mice) have blunted insulin-depen-
dent vasodilator responses in aortic rings but preserved
vasorelaxant responses to ACh at a young age (20).
However, as IRKO mice age, they develop blunting of
ACh-mediated aortic relaxation secondary to increased
superoxide production (24). The present report indicates a
similar mechanism of endothelial dysfunction and sug-
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FIG. 5. Assessment of CMEC superoxide production. A: In situ ROS
generation in CMECs was assessed through measurement of peak
ﬂuorescence of CMECs exposed to 2 mol/l DHE (5 min). CMECs from
ESMIRO mice showed signiﬁcantly greater ﬂuorescence than wild type
(WT); n  6 mice, *P < 0.05. B: Using CMEC homogenates, 5 mol/l
lucigenin-enhanced chemiluminescence was repeated. Similar to the
results observed in whole aortae, this suggested increased NADPH-
dependent superoxide production in ESMIRO CMECs at baseline.
Superoxide levels were reduced by tiron and DPI but not by L-NAME.
*P < 0.001 with inhibitor compared with wild-type baseline; #P < 0.001
with inhibitor compared with ESMIRO baseline. ILU, integrated light
units.
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FIG. 6. Real-time RT-PCR examination of Nox2 and Nox4 mRNA
expression in CMECs and whole aortae (relative to -actin). A and C:
ESMIRO mice demonstrate signiﬁcantly increased Nox2 and Nox4
mRNA expression in CMECs. B and D: A similar pattern of expression
is noted in aortae. CMECs, n  6; aortae, n  5. *P < 0.05. WT, wild
type.
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signaling at the level of the endothelial cell may lead to
increased superoxide generation and therefore a reduction
in NO bioavailability.
Although we used a Tie2 promoter construct to direct
endothelial cell–speciﬁc expression, there is now some
evidence that Tie2 may also be expressed within a small
subset (2–7%) of circulating blood monocytes (40). This
raises the possibility that the increased superoxide dem-
onstrated in whole ESMIRO aortae could result from
circulating hematopoietic cells. However, this is unlikely
in view of the small population of cells involved and the
fact that endothelial dysfunction was conﬁrmed in isolated
aorta in the organ bath. Furthermore, both DHE ﬂuores-
cence and lucigenin-enhanced chemiluminescence per-
formed on isolated endothelial cells from ESMIRO mice
conﬁrmed increased NADPH-dependent superoxide pro-
duction by these cells.
Interestingly, in contrast with the data from Kahn and
colleagues (14) and the vascular endothelium insulin re-
ceptor knockout (VENIRKO) mouse, total eNOS expres-
sion was not downregulated in our model either at mRNA
or protein level. There are a number of potential explana-
tions for this difference. The VENIRKO mouse is a condi-
tional knockout model generated using a Cre-lox
approach, whereas the ESMIRO mouse presented in the
current report demonstrates overexpression of mutant
insulin receptors with a dominant-negative action. This
mutant receptor has been demonstrated previously to bind
insulin normally but to lack tyrosine kinase activity. These
fundamental differences between the models may explain
the differences observed. It is also unclear from the
VENIRKO paper at which age the mice were studied. This
may be important because we have recently demonstrated
that mice with haploinsufﬁciency of the insulin receptor
are prone to an age-related decline in endothelial function
(24).
Three different methods were used to conﬁrm the
increased superoxide production in the ESMIRO mouse.
Perhaps most notably, a SOD mimetic restored endothelial
function through conversion of superoxide to hydrogen
peroxide. The source of increased endothelial superoxide
in the study does, however, remain to be fully deﬁned.
NADPH oxidases are recognized as major sources of ROS
in the vasculature (41) and are dysregulated in models of
type 2 diabetes, insulin resistance, and obesity (42–45).
Several isoforms of these enzymes have been described
previously (46), among which Nox2 and Nox4 have been
implicated in increased oxidase activity in obesity (47,48)
and in insulin signaling in nonendothelial tissues (49). An
interesting ﬁnding in the current study was the increase in
Nox2 and Nox4 mRNA levels in aortae and CMECs of
ESMIRO mice, which would be in keeping with a role for
NADPH oxidases in the increased superoxide generation.
However, in the absence of available good selective inhib-
itors of these enzymes, deﬁnitive evidence of their involve-
ment would require additional studies probably involving
appropriate gene-modiﬁed models.
The mechanism of Nox2 and Nox4 upregulation in the
endothelium requires further elucidation. Recent studies
have suggested an association between insulin signaling
via the PI 3-kinase pathway and Nox4 expression (49). It
has been hypothesized that Nox4 activity may maintain
insulin sensitivity. Therefore, in our model Nox4 may be
upregulated to compensate for the impaired endothelial
insulin signaling. Future studies would also clarify
whether Nox2 and Nox4 are upregulated in aortic tissues
other than the endothelium.
Finally, the ESMIRO demonstrates a reduced phospho-
eNOS–to–eNOS ratio compared with wild type both after
stimulation with insulin and at baseline. The latter differ-
ence was small. This does raise the possibility that re-
duced eNOS activity may contribute to the endothelial
dysfunction in the ESMIRO irrespective of preserved
eNOS expression. This requires further investigation.
Endothelial insulin resistance and glucose homeosta-
sis. Despite a substantial defect of insulin signaling in
vascular endothelial cells, we found no demonstrable
abnormality in the metabolic phenotype of ESMIRO mice.
In fact, consistent with the ﬁndings in VENIRKO mice (14),
there was a tendency for an improvement in insulin
sensitivity during the later stages of insulin tolerance
testing. Although a euglycemic insulin clamp may have
revealed more subtle abnormalities in glucose homeosta-
sis, our data and those from Kahn and colleagues (14) do
not support a nonredundant role for insulin-induced endo-
thelial NO release in blood glucose homeostasis.
Conclusions. The observed phenotype of ESMIRO mice
indicates that abnormal endothelium-dependent vasodila-
tation in the context of insulin resistance may be attribut-
able to impaired insulin signaling at the level of the
endothelial cell per se, independent of other abnormalities
that are the result of global insulin resistance. Therefore,
the integrity of endothelial cell insulin signaling plays a
key role in determining conduit vessel endothelial function
and NO bioavailability in response to conventional (non-
insulin receptor–mediated) agonists.
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